147 related articles for article (PubMed ID: 7706163)
1. In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis.
Pastor A; Pemán J; Cantón E
J Antimicrob Chemother; 1994 Nov; 34(5):679-85. PubMed ID: 7706163
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between the sensitivity of Pseudomonas aeruginosa and the post-antibiotic effect of sparfloxacin and ciprofloxacin].
Pastor A; Cantón E; Pemán J
Rev Esp Quimioter; 1998 Dec; 11(4):333-8. PubMed ID: 9990147
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.
Louie A; Baltch AL; Ritz WJ; Smith RP
J Antimicrob Chemother; 1991 Jun; 27(6):793-9. PubMed ID: 1657857
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
6. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of sparfloxacin compared with those of five other quinolones.
Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
[TBL] [Abstract][Full Text] [Related]
8. Postantibiotic effect, and postantibiotic effect of subinhibitory concentrations, of sparfloxacin on gram-negative bacteria.
Odenholt-Tornqvist I; Bengtsson S
Chemotherapy; 1994; 40(1):30-6. PubMed ID: 8306813
[TBL] [Abstract][Full Text] [Related]
9. [Study of quinolones resistance in Escherichia coli, Staphylococcus aureus and Pseudomonas areuginosa].
Feng P; Yu R; Xia P; Lü X; Zhu S
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):501-4. PubMed ID: 12528531
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
[TBL] [Abstract][Full Text] [Related]
11. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
Houston AK; Jones RN
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
[TBL] [Abstract][Full Text] [Related]
12. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of subinhibitory concentrations of ciprofloxacin against Pseudomonas aeruginosa as determined by the killing curve method and the postantibiotic effect.
Zhanel GG; Crampton J; Kim S; Nicolle LE; Davidson RJ; Hoban DJ
Chemotherapy; 1992; 38(6):388-94. PubMed ID: 1288962
[TBL] [Abstract][Full Text] [Related]
14. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
[TBL] [Abstract][Full Text] [Related]
15. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
Odenholt I; Löwdin E; Cars O
Antimicrob Agents Chemother; 2003 Oct; 47(10):3352-6. PubMed ID: 14506057
[TBL] [Abstract][Full Text] [Related]
16. Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
Majtán V; Hostacká A
Folia Microbiol (Praha); 1996; 41(3):228-32. PubMed ID: 9449771
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens.
Stratton CW; Weeks LS
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):29S-34S. PubMed ID: 2791495
[TBL] [Abstract][Full Text] [Related]
18. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
[TBL] [Abstract][Full Text] [Related]
19. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
Bauernfeind A
J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
